Research
Home  >  Research > Research groups > D > Dianes farmacològiques en inflamació i malalties metabòliques

Dianes farmacològiques en inflamació i malalties metabòliques

General information

Recogised research group by the Generalitat de Catalunya

Activation of PPARdelta has been proposed as a therapeutic target to prevent metabolic diseases with an inflammatory basis, such as insulin resistance and type 2 diabetes mellitus. However, the putative molecular mechanisms by which PPARdelta activation might be used to prevent or treat these pathologies remain to be established. We thus aim to examine the effects of PPARdelta activators on hyperinsulinemia and inflammation caused by enhanced plasma free fatty acids, cytokines or advanced glycation endproducts in cellular and animal models of insulin resistance. In addition, we are interested in the link between hyperinsulinemia, inflammation and Alzhimer's disease and the potential role of PPARdelta.

UNESCO codes:

Key words:

Thematic area: 5000 - Ciències Mèdiques i de la Salut

  • Follow us:
  • Button to access University of Barcelona's Facebook profile
  • Button to access University of Barcelona's Twitter profile
  • Button to access University of Barcelona's Instagram profile
  • Button to access University of Barcelona's Linkedin profile
  • Button to access University of Barcelona's Youtube profile
  • Button to access University of Barcelona's Google+ profile
  • ??? peu.flickr.alt ???
Member of International recognition of excellence HR Excellence in Research logo del leru - League of European Research Universities logo del bkc - campus excel·lència logo del health universitat de barcelona campus

© Universitat de Barcelona